

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2837832/publications.pdf>

Version: 2024-02-01

61
papers

3,215
citations

172457

29
h-index

149698

56
g-index

61
all docs

61
docs citations

61
times ranked

4819
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of the seleno-transcriptome expression between human non-cancerous mammary epithelial cells and two human breast cancer cell lines. <i>Oncology Letters</i> , 2017, 13, 2411-2417.	1.8	22
2	Evaluation of the Selenotranscriptome Expression in Two Hepatocellular Carcinoma Cell Lines. <i>Analytical Cellular Pathology</i> , 2015, 2015, 1-6.	1.4	27
3	The Cytokine Profile in Patients with Hepatocellular Carcinoma and Type 2 Diabetes. <i>PLoS ONE</i> , 2015, 10, e0134594.	2.5	21
4	Oxidative Stress and Mitochondrial Dysfunction across Broad-Ranging Pathologies: Toward Mitochondria-Targeted Clinical Strategies. <i>Oxidative Medicine and Cellular Longevity</i> , 2014, 2014, 1-27.	4.0	108
5	Synergistic Antitumor Effect of Doxorubicin and Tacrolimus (FK506) on Hepatocellular Carcinoma Cell Lines. <i>Scientific World Journal</i> , The, 2014, 2014, 1-9.	2.1	15
6	Current Experience in Testing Mitochondrial Nutrients in Disorders Featuring Oxidative Stress and Mitochondrial Dysfunction: Rational Design of Chemoprevention Trials. <i>International Journal of Molecular Sciences</i> , 2014, 15, 20169-20208.	4.1	20
7	Structure–function relationship and evolutionary history of the human selenoprotein M (SelM) found over-expressed in hepatocellular carcinoma. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2014, 1844, 447-456.	2.3	17
8	Basic amino acids and dimethylarginines targeted metabolomics discriminates primary hepatocarcinoma from hepatic colorectal metastases. <i>Metabolomics</i> , 2014, 10, 1026-1035.	3.0	7
9	Peptides targeting chemokine receptor CXCR4: structural behavior and biological binding studies. <i>Journal of Peptide Science</i> , 2014, 20, 270-278.	1.4	8
10	Potential Anti-Inflammatory Effects of the Hydrophilic Fraction of Pomegranate (Punica granatum L.) Seed Oil on Breast Cancer Cell Lines. <i>Molecules</i> , 2014, 19, 8644-8660.	3.8	66
11	Vitamin C Effect on Mitoxantrone-Induced Cytotoxicity in Human Breast Cancer Cell Lines. <i>PLoS ONE</i> , 2014, 9, e115287.	2.5	38
12	A Holistic Approach to Study the Effects of Natural Antioxidants on Inflammation and Liver Cancer. <i>Cancer Treatment and Research</i> , 2014, 159, 311-323.	0.5	12
13	Cytokine profile evaluation in patients with hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2014, 20, 9261-9.	3.3	23
14	From clinical description, to in vitro and animal studies, and backward to patients: Oxidative stress and mitochondrial dysfunction in Fanconi anemia. <i>Free Radical Biology and Medicine</i> , 2013, 58, 118-125.	2.9	24
15	Evaluation of Selenite Effects on Selenoproteins and Cytokine in Human Hepatoma Cell Lines. <i>Molecules</i> , 2013, 18, 2549-2562.	3.8	30
16	Sjögren's syndrome-associated oxidative stress and mitochondrial dysfunction: Prospects for chemoprevention trials. <i>Free Radical Research</i> , 2013, 47, 71-73.	3.3	51
17	Dissimilar cytokine patterns in different human liver and colon cancer cell lines. <i>Cytokine</i> , 2013, 64, 584-589.	3.2	4
18	Regulatory T cells, interleukin (IL)-6, IL-8, Vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma. <i>BJU International</i> , 2013, 112, 686-696.	2.5	70

#	ARTICLE	IF	CITATIONS
19	Common structural interactions between the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural ligands, CXCL11 and CXCL12, by a modeling approach. <i>Cytokine</i> , 2013, 64, 316-321.	3.2	22
20	Bone marrow cell transcripts from Fanconi anaemia patients reveal <i>in vivo</i> alterations in mitochondrial, redox and DNA repair pathways. <i>European Journal of Haematology</i> , 2013, 91, 141-151.	2.2	19
21	Cancer biomarker profiling in patients with chronic hepatitis C virus, liver cirrhosis and hepatocellular carcinoma. <i>Oncology Reports</i> , 2013, 29, 2163-2168.	2.6	18
22	Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases. <i>PLoS ONE</i> , 2013, 8, e74548.	2.5	76
23	Oxidative stress in Fanconi anaemia: from cells and molecules towards prospects in clinical management. <i>Biological Chemistry</i> , 2012, 393, 11-21.	2.5	57
24	Oxidative Stress and Mitochondrial Dysfunction in Down Syndrome. <i>Advances in Experimental Medicine and Biology</i> , 2012, 724, 291-299.	1.6	100
25	Cytokine Profile of Patients with Type 2 Diabetes and/or Chronic Hepatitis C Infection. <i>PLoS ONE</i> , 2012, 7, e39486.	2.5	27
26	The N-terminal Region of CXCL11 as Structural Template for CXCR3 Molecular Recognition: Synthesis, Conformational Analysis, and Binding Studies. <i>Chemical Biology and Drug Design</i> , 2012, 80, 254-265.	3.2	14
27	Effects of Lipoic Acid, Caffeic Acid and a Synthesized Lipoyl-Caffeic Conjugate on Human Hepatoma Cell Lines. <i>Molecules</i> , 2011, 16, 6365-6377.	3.8	34
28	A possible predictive marker of progression for hepatocellular carcinoma. <i>Oncology Letters</i> , 2011, 2, 1247-1251.	1.8	21
29	Structural and functional studies of the human selenium binding protein-1 and its involvement in hepatocellular carcinoma. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2011, 1814, 513-522.	2.3	51
30	CD4+CD45RA+CXCR4+ lymphocytes are inversely associated with progression in stages I-III melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 511-517.	4.2	1
31	Mitochondrial dysfunction in some oxidative stress-related genetic diseases: Ataxia-Telangiectasia, Down Syndrome, Fanconi Anaemia and Werner Syndrome. <i>Biogerontology</i> , 2010, 11, 401-419.	3.9	106
32	HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. <i>Clinical Immunology</i> , 2010, 134, 237-250.	3.2	131
33	Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment. <i>Journal of Translational Medicine</i> , 2010, 8, 109.	4.4	27
34	Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2220-2226.	1.6	163
35	Serum cytokine levels in patients with hepatocellular carcinoma. <i>European Cytokine Network</i> , 2010, 21, 99-104.	2.0	45
36	Serum cytokine levels as putative prognostic markers in the progression of chronic HCV hepatitis to cirrhosis. <i>European Cytokine Network</i> , 2010, 21, 251-6.	2.0	36

#	ARTICLE	IF	CITATIONS
37	Impaired diastolic function in naïve untreated human immunodeficiency virus infected patients. World Journal of Cardiology, 2010, 2, 98.	1.5	16
38	Human Cytokine: a new challenge for systems biology. Bioinformatics, 2010, 5, 166-167.	0.5	29
39	Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis, 2009, 204, 586-589.	0.8	75
40	Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy. European Journal of Cancer, 2007, 43, 137-143.	2.8	28
41	Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 86-91.	2.8	43
42	CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type. Cancer Immunology, Immunotherapy, 2007, 56, 1589-1595.	4.2	36
43	Soluble interleukin-2 receptor in stage III melanoma. Cytokine, 2006, 33, 150-155.	3.2	24
44	Multiple evidence for an early age pro-oxidant state in Down Syndrome patients. Biogerontology, 2006, 7, 211-220.	3.9	70
45	Adjuvant treatment of malignant melanoma: Where are we?. Critical Reviews in Oncology/Hematology, 2006, 57, 45-52.	4.4	10
46	Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma. BMC Cancer, 2006, 6, 266.	2.6	19
47	Overexpression of Both CXC Chemokine Receptor 4 and Vascular Endothelial Growth Factor Proteins Predicts Early Distant Relapse in Stage II-III Colorectal Cancer Patients. Clinical Cancer Research, 2006, 12, 2795-2803.	7.0	158
48	Human Melanoma Metastases Express Functional CXCR4. Clinical Cancer Research, 2006, 12, 2427-2433.	7.0	114
49	Evidence of publication bias in clinical trials of biotherapies for solid tumors. Cancer, 2005, 103, 653-653.	4.1	5
50	Prospective clinical trials of biotherapies in solid tumors: a 5-year survey. Cancer Immunology, Immunotherapy, 2005, 54, 44-50.	4.2	12
51	Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells. Cancer Immunology, Immunotherapy, 2005, 54, 781-791.	4.2	78
52	Expression of CXCR4 Predicts Poor Prognosis in Patients with Malignant Melanoma. Clinical Cancer Research, 2005, 11, 1835-1841.	7.0	260
53	Pegylated Arginine Deiminase Treatment of Patients With Metastatic Melanoma: Results From Phase I and II Studies. Journal of Clinical Oncology, 2005, 23, 7660-7668.	1.6	218
54	In vivoprooxidant state in Werner syndrome (WS): Results from three WS patients and two WS heterozygotes. Free Radical Research, 2005, 39, 529-533.	3.3	44

#	ARTICLE	IF	CITATIONS
55	Pegylated Arginine Deiminase Treatment of Patients With Unresectable Hepatocellular Carcinoma: Results From Phase I/II Studies. <i>Journal of Clinical Oncology</i> , 2004, 22, 1815-1822.	1.6	238
56	Prognostic Value of Circulating Melanoma Cells Detected by Reverse Transcriptase-Polymerase Chain Reaction. <i>Journal of Clinical Oncology</i> , 2003, 21, 767-773.	1.6	91
57	Mutation analysis of candidate genes in melanoma-prone families. <i>Melanoma Research</i> , 2003, 13, 571-579.	1.2	11
58	Detection of Occult Melanoma Cells in Paraffin-Embedded Histologically Negative Sentinel Lymph Nodes Using a Reverse Transcriptase Polymerase Chain Reaction Assay. <i>Journal of Clinical Oncology</i> , 2001, 19, 1437-1443.	1.6	63
59	Intermediate dose recombinant interferon- γ as second-line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon. <i>Cancer</i> , 2000, 89, 1490-1494.	4.1	9
60	Soluble Interleukin-2 Receptor Levels in Hepatocellular Cancer: a More Sensitive Marker Than Alfa Fetoprotein. <i>Annals of Surgical Oncology</i> , 1999, 6, 178-185.	1.5	37
61	Immunological Phenotype Analysis of Patients with Fanconi's Anaemia and Their Family Members. <i>Acta Haematologica</i> , 1998, 100, 39-43.	1.4	16